Adc Therapeutics SA DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
ADC Therapeutics SA announces its 2026 Annual General Meeting of Shareholders, to be held virtually on June 1, 2026, with key proposals including financial statement approval, compensation review, director reelections, and amendments to share capital.
NYSE
DEFA14A: ADC Therapeutics SA Seeks Shareholder Approval for Key Proposals at Upcoming Annual General Meeting
ADC Therapeutics SA is holding its Annual General Meeting on June 3, 2025, seeking shareholder approval for proposals including financial statement approval, director elections, compensation matters, and an increase in conditional share capital.
NYSE
ADC Therapeutics has scheduled its 2025 Annual General Meeting for June 3, 2025, to address key proposals including financial approvals, director elections, and executive compensation.
NYSE
ADC Therapeutics is holding an extraordinary shareholder meeting to vote on proposals to increase the company's capital range and conditional share capital.
NYSE
DEF 14A: ADC Therapeutics Seeks Shareholder Approval for Capital Range and Conditional Share Capital Increase
ADC Therapeutics is holding a special meeting to seek shareholder approval for amendments to its articles of association to increase its capital range and conditional share capital for financing, acquisitions, and other purposes.
NYSE
ADC Therapeutics SA will hold its Annual General Meeting on June 13, 2024, to vote on proposals including the approval of financial statements, director re-elections, and compensation matters.
NYSE
ADC Therapeutics SA's upcoming annual general meeting on June 13, 2024, will address key proposals including financial statement approvals, director elections, and compensation matters.